Increased Inflammation, Reduced Plasma Phospholipid Eicosapentaenoic Acid and Reduced Antioxidant Potential of Treated Hypertensive Patients with Metabolic Syndrome

다국어 초록 (Multilingual Abstract)

Purpose: In the present study, we tested whether the presence of metabolic syndrome (MetS) would worsen the
features of inflammation, plasma omega 3 fatty acid levels and antioxidant potential in treated hypertensive
patients. Materials and Methods: Two groups were classified by the components of MetS: a reference group of
treated hypertensive subjects: hypertension (HTN) group (n = 39) and with more than two additional MetS
components: HTN with Mets group (n = 40). We further compared the parameters between HTN group and HTN
with MetS group. Results: The results showed that age (p < 0.001) and body mass index (BMI) (p < 0.001) were
significantly different between HTN group and HTN with MetS group. Age- and BMI-adjusted total radical
trapping antioxidant potential (TRAP) (p < 0.01) was significantly lower, whereas age- and BMI-adjusted CD (p <
0.05) and interleukin (IL) 6 (p < 0.05) were significantly higher in HTN with MetS group than in HTN group.
Moreover, HTN with MetS group had significantly lower levels of age- and BMI-adjusted plasma phospholipid
eicosapentaenoic acid (EPA) than HTN group (p < 0.05). On the other hand, the levels of age- and BMI-adjusted
intracellular cell adhesion molecule-1 (ICAM-1), adiponectin and high molecular weight (HMW)-adiponectin were
not significantly different between the groups. Conclusion: In conclusion, our results showed increased
inflammatory marker, reduced antioxidant potential and EPA levels in treated hypertensive patients in the presence
of MetS, suggesting the importance of changes of therapeutic lifestyle to modify the features of MetS.

참고문헌 (Reference)

1 Schiffrin EL, "Vascular stiffening and arterial compliance, in Implications for systolic blood pressure" 17 : 39S-48S, 2004

2 Rice-Evans C, "Total antioxidant status in plasma and body fluids, in Methods in Enzymology" Academic Press 279-293, 1994

3 Harris WS, "The omega-3 index as a risk factor for coronary heart disease" 87 : 1997S-2002S, 2008

4 McNeill AM, "The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study" 28 : 385-390, 2005

5 Kressel G, "Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk" 202 : 263-271, 2009

6 "Steering Committee of the WHO Western Pacific Region, IASO & IOTF. The Asia-Pacific perspective: redefining obesity and its treatment. Australia"

7 Lemaitre RN, "Siscovick DS. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study" 77 : 319-325, 2003

8 Jacobson TA, "Secondary prevention of coronary artery disease with omega-3 fatty acids" 98 : 61i-70i, 2006

9 Hunt KJ, "San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study" 110 : 1251-1257, 2004

10 Schillaci G, "Prognostic value of the metabolic syndrome in essential hypertension" 43 : 1817-1822, 2004

11 Lemaitre RN, "Plasma phospholipid trans fatty acids, fatal ischemic heart disease, and sudden cardiac death in older adults: the cardiovascular health study" 114 : 209-215, 2006

12 Su HM, "Peroxisomal straight-chain Acyl-CoA oxidase and D-bifunctional protein are essential for the retroconversion step in docosahexaenoic acid synthesis" 276 : 38115-38120, 2001

13 Grattagliano I, "Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis" 19 : 491-504, 2008

14 Harris WS, "Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation" 110 : 1645-1649, 2004

15 Lteif AA, "Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks" 112 : 32-38, 2005

16 Leoncini G, "Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients" 257 : 454-460, 2005

17 Cuspidi C, "Metabolic syndrome and target organ damage in untreated essential hypertensives" 22 : 1991-1998, 2004

18 Ford ES, "Metabolic syndrome and incident diabetes: current state of the evidence" 31 : 1898-1904, 2008

19 Van Guilder GP, "Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults" 14 : 2127-2131, 2006

20 Hansson GK, "Inflammation, atherosclerosis, and coronary artery disease" 352 : 1685-1695, 2005

21 Furukawa S, "Increased oxidative stress in obesity and its impact on metabolic syndrome" 114 : 1752-1761, 2004

22 Hotamisligil GS, "Increased adipose tissue expression of tumor necrosis factoralpha in human obesity and insulin resistance" 95 : 2409-2415, 1995

23 Mattews DR, "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man" 28 : 412-419, 1985

24 Seino Y, "High molecular weight multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men" 56 : 1493-1499, 2007

25 Hu FB, "Fish and omega-3 fatty acid intake and risk of coronary heart disease in women" 287 : 1815-1821, 2002

26 Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults, "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)" 285 : 2486-2497, 2001

27 Nakazono K, "Does superoxide underlie the pathogenesis of hypertension?" 10045-10048, 1991

28 Lepage G, "Direct transesterification of all classes of lipids in a one-step reaction" 27 : 114-120, 1986

29 Schillaci G, "Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and Women" 47 : 881-886, 2006

30 Grundy SM, "Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement" 112 : 2735-2752, 2005

31 Aso Y, "Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin" 55 : 1954-1960, 2006

32 Aizawa Y, "Clustering trend of components of metabolic syndrome" 121 : 117-118, 2007

33 Toshima S, "Circulating oxidized low density lipoprotein levels, in A biochemical risk marker for coronary heart disease" 20 : 2243-2247, 2000

34 Hotta K, "Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys" 50 : 1126-1133, 2001

35 Isomaa B, "Cardiovascular morbidity and mortality associated with the metabolic syndrome" 24 : 683-689, 2001

36 Rutter MK, "C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study" 110 : 380-385, 2004

37 Ahotupa M, "Baseline diene conjugation in LDL lipids as a direct measure of in vivo LDL oxidation" 31 : 257-261, 1998

38 Lara-Castro C, "Adiponectin multimeric complexes and the metabolic syndrome trait cluster" 55 : 249-259, 2006